Drs. David Siderovski and Abbot Clark receive NEI grant to explore new treatments for glaucoma
January 31, 2025 • CBTS, faculty, P&N, Research
Could a therapeutic target for glaucoma that was once considered “undruggable” be the key to a first-of-its-kind treatment?
That was the question posed among friends and colleagues Dr. David Siderovski and Dr. Abbot Clark during one of their regular breakfast meetings at the Torched Apron Grill on The University of North Texas Health Science Center at Fort Worth campus.
That friendly conversation launched a collaborative project that just earned new research funding from The National Eye Institute of the National Institutes of Health. And it could lead to a new treatment for glaucoma, the leading cause of irreversible vision loss and blindness that affects more than 80 million people worldwide.
The project will target the bone morphogenic protein signaling antagonist Gremlin-1, seen to be elevated in the eyes of patients suffering from glaucoma. GREM1 causes a protein buildup in the front of the eye that increases the pressure within, leading to progressive vision loss and blindness if unchecked.
Read more: CBTS researchers receive National Eye Institute grant
Award number R21EY036503. The content of this release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Social media